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Individualization of patient care is creating an envisioned future in which practitioners
wield a new doctor’s bag deploying individual molecular, genetic, cellular, and systems
profiles. 1,2 These emerging tools are refining traditional paradigms of disease
palliation into nuanced patient management algorithms employing prognostic risk
stratification, therapeutic response prediction, and adverse event avoidance. 3,4
Advancing technologies are enabling a shift to more proximal nodes along the continuum
of pathobiology. Innovations in biomarker platforms, genomic profiling, and
molecular imaging reveal the earliest stages of pathophysiology, 5–7 limiting systems
disruption to cells and tissues while preserving integrated organ function, enabling risk
mitigation and disease prevention. 8–10 At even earlier stages, the interplay of genetics,
epigenetics, environmental exposures, nutrition, and lifestyle define a roadmap to the
clinical nonpareil of disease avoidance. 11 Broad dissemination of these principles into
global healthcare paradigms changes the dynamics and economics of health across

populations. 11–13 Realization of these algorithms transforms healthcare from the
tradition of relieving pain and suffering to a future maintaining longitudinal wellness and
healthy aging. 12 , 14 , 15
While coevolution of emerging technologies offers unprecedented opportunities for risk
mitigation and disease prevention, their impact on the science of healthcare delivery
is restricted by the stochastic nature of disease evolution. Symptomatic disease rises to
medical attention because disruption of integrated organ function produces physical
manifestations, initiating the reactive palliative model of healthcare delivery. In
contrast, early evolution of disease confined to cells and tissues, often the stage most
amenable to cure, evades medical attention because it is asymptomatic and, consequently,
silent. The time course of progression from asymptomatic to symptomatic disease
states, a critical element in therapy lag, reflects individual genetic and environmental
parameters and their impact on diseasespecific pathobiology; organs affected and their
functional reserve; and kinetics of disease progression. These elements conspire
to produce uniquely individual profiles of disease progression whose temporality often
defies prediction, relegating healthcare delivery to reactive palliation, rather than
proactive anticipatory risk mitigation and prevention. 4 , 14 , 15
This paradigm is exemplified by cardiovascular disease, the leading cause of morbidity
and mortality worldwide, afflicting 15% of the global population. 16 This is the principle
cause of coronary artery disease, which underlies the 10 million myocardial infarctions
that occur each year worldwide. 17 In the United States, 18 million
Americans live with coronary artery disease that produces more than 1 million
myocardial infarctions and 0.5 million deaths each year at a cost of $36 billion, an
economic burden that will escalate to more than $100 billion by 2030. 18 The
pathobiology includes critical progressive narrowing of coronary arteries by expanding
atheromatous plaque, which limits blood flow to downstream myocardium. 17 The erratic
kinetics of progression of atheromatous growth and vessel narrowing reflect genetic,
environmental, lifestyle, and other unknown factors whose interactions remain
undefined. The acute event at the center of morbidity and mortality, myocardial
infarction, is precipitated by the unpredictable rupture of these plaques, creating a
thrombogenic surface precipitating clot formation and acute vessel obstruction. 17 , 19
The severity of organ damage, in part, reflects the reservoir of collateral circulation to
at-risk myocardium downstream from the occlusion. An essential therapeutic paradigm
minimizing mortality is treatment by clotlysis or angioplasty at the earliest time after the
onset of a myocardial infarction. 20 Here, “time is muscle,” and delays in treatment result
in irretrievable loss of myocardium associated with diminished cardiac function.
This example highlights the essential contribution of the stochastic nature of disease
progression to morbidity and mortality. Even in the context of established risk factors, for
example hypercholesterolemia, hypertension, or diabetes, and the associated certainty of
the presence of coronary artery disease, the temporal kinetics of disease progression and
plaque rupture remain unpredictable in individual patients. If there was certainty to the
timing of myocardial infarctions in the minutes to hour time scale, clotlysis, or
angioplasty could be initiated at the earliest possible moment, minimizing myocardial

damage and maximizing cardiac function. 20 Beyond optimizing the timing of acute
interventions, if plaque rupture could be predicted on the hours to day time
scale, myocardial infarctions and the associated morbidity and mortality could be
eliminated. The ability to predict and prevent myocardial infarctions in real time could
transform the science and economics of healthcare delivery globally.
This discussion underscores the clinical management gap for diseases whose progression
is individualized and stochastic and whose culmination is catastrophic, for example
coronary artery disease, heart failure, graft rejection, cancer, or stroke. This gap
specifically encompasses the dimension of time, illustrated by the availability of
effective therapeutic interventions that interrupt, reverse, or prevent permanent organ
damage but the inability to predict the kinetics of the catastrophic event. Management of
these conditions could be transformed by technologies providing continuous longitudinal
surveillance that identify the earliest stages in evolution of acute events in a time frame
facilitating effective therapeutic interventions. This unmet clinical need, in which
application of advances in individualized medicine are limited by unpredictable kinetics
of pathobiology, can be addressed by the emerging science of implantable biosensors, a
disruptive technology that can bridge the temporal gap in disease management.
Implantable biosensors are moving from the realm of science fiction ( Star Trek tricorder,
Six Million Dollar Man ) into mainstream healthcare. Sensors that detect cardiac
arrhythmias are integral to automatic implantable defibrillators. 21 Implantable glucose
monitors can assess glycemia in real time in diabetes. 22 Pacemakers deconvolute the
cardiac cycle to maintain adequate perfusion. 21 The evolution of these first generation
applications into complex systems-level devices that transform healthcare from palliation
to prevention is enabled by the convergence of exponential advances in prognostic and
predictive biomarker discovery, nanodevices, material sciences, wireless data transfer,
medical informatics, and microscale energy technology. 23 The intersection of these
disparate scientific communities has been catalyzed by the revolution in biology, which is
providing healthcare solutions that must be actualized at the interface of science,
medicine, engineering, and informatics.
The dimensionality of implantable biosensors encompassing axes of time, disease, and
therapy, provides a context for their evolution and application. The time dimension
comprises elements of stability, periodicity, and kinetics. Continuous monitoring could
benefit processes that are highly dynamic, for example electrical activity underlying
epilepsy. Similarly, longitudinal surveillance could identify imminent exacerbations in
conditions with oscillating progression, for example relapsing and remitting diseases like
multiple sclerosis. Also, it could benefit diseases that evolve slowly and
asymptomatically over long durations, like coronary artery disease and cancer. In the
disease dimension, elements include damage, reversibility, and severity. Conditions
in which damage is initially silent, progressive and cumulative, for example the sequelae
of microvascular disease including neuropathy, nephropathy, and retinopathy in diabetes,
might benefit from continuous monitoring. Also, disease processes that are reversible, in
which outcomes can be infl uenced by therapeutic intervention, are candidates for
longitudinal monitoring. Of course, the severity of disease and its impact on end organ

function, quality of life, and productivity is a key element in considering the value
proposition of continuous monitoring. Finally, the dimension of therapy considers the
elements of efficacy, therapeutic index, and interindividual variability. Resource
allocation for developing and deploying biosensors advances healthcare management
only within the context of the availability of highly effective therapeutic interventions
that alter the course of the disease. Also, continuous monitoring could facilitate the
application of drugs with narrow therapeutic indices, replacing intermittent ex vivo
therapeutic drug monitoring that can miss the window of toxicity. Finally, drugs in
which there is genomically based broad interindividual variability in either therapeutic
responses or adverse reactions could benefit from longitudinal monitoring that optimizes
therapy. 24,25
Current models for continuous biosensor monitoring specifically focus on applications
that bridge the temporal gap between disease progression and acute exacerbation, an
extension of the established reactive paradigm of disease palliation. For example,
automatic implantable defibrillators detect the earliest stages of an arrhythmia and deliver
therapeutic cardioversion to interrupt what could be a catastrophic event. 21 Here, the
sensor is dedicated to detecting a single output (electrical), there are minimum external
data handling requirements in this closedloop system, and the downstream actions
entrained by sensor activation (cardioversion) are stereotypic, obviating complex
clinical response protocols. However, as biosensor platforms advance in sophistication at
the biology–engineering interface, they will drive coevolution of healthcare to a proactive
paradigm of risk mitigation and disease prevention. On the immediate horizon, the nextgeneration bionic pancreas will encompass closed-loop biosensor systems that
continuously monitor serum glucose and, through an informatics interface with complex
response algorithms, automatically deliver insulin, to maintain steady state euglycemia
and prevent microvascular disease in diabetic patients. 22 At the next level, complex
biosensor systems strategically deployed in multiple anatomical compartments that
integrate panels of physiological and biochemical parameters will create a data-driven
management paradigm for complex life-long conditions, for example cancer, obesity and
metabolic diseases, and cardiovascular disease. These higher order biosensor systems
will demand innovation in data integration and reporting, wireless data transfer and
telemetry, and clinical response algorithms. 23 Beyond disease risk mitigation and
prevention, one envisioned future includes complex integrated biosensor architectures
that enable longitudinal wellness and healthy aging. These systems will incorporate
physiological, as well as disease diagnosis, prognosis, and prediction, analytic
capabilities. Th ey will have hierarchical data response algorithms that address
physiological and pathophysiological deviations. 23 Moreover, these systems will
permit the evolution of decentralized healthcare delivery, where health maintenance and
disease management occur outside the boundaries of traditional healthcare structures like
hospitals, facilitated by innovations in medical informatics, including electronic data
transfer, integration, storage, and management. 12
While this envisioned future incorporating continuous biosensor monitoring is poised to
transform healthcare delivery, the hurdles to actualization are formidable and should not
be underestimated. For example, there is an essential dependence on identifying and

validating biomarkers of disease risk and early disease detection. The revolution in the
new biology has provided unparalleled biomarker discovery platforms, evidenced
by the near-daily identifi cation of unique biomolecules associated with pathophysiology.
7 Yet, there continues to be a paucity of disease biomarkers that are analytically
validated, qualified in their association with disease and proven in their prognostic or
predictive utility. 26 Substantial bioengineering challenges focus on biocompatibility,
durability, and performance in biosensors for diseases that may require life-long
monitoring. Energy scientists will need to develop enduring sources of power at micro,
nano, or atomic scale, compatible with long-term residence in vivo. Informatics engineers
must create algorithms that assemble and integrate longitudinal data collected over vast
arrays of (patho) physiological, cellular, and biochemical analytes to produce systemslevel profiles of health and disease that are actionable. Wireless data transfer algorithms
will need to be mapped to provide data at appropriate intervals that hierarchically
subserve maintenance of longitudinal wellness, longitudinal monitoring of disease
progression, or acute prevention of unpredictable catastrophic events. Moreover, clinical
algorithms for effectively responding to these data will need to be established,
accompanied by systems that can deploy response resources to patients.
Beyond biology, engineering, and clinical challenges, there are regulatory and policy
considerations surrounding this disruptive innovation. While clinical development and
regulatory approval strategies are well established for traditional drugs and devices,
complex implantable biosensor systems represent an amalgamation of technologies
cutting across many disparate domains, and new paradigms to evaluate their safety and
effi cacy will be necessary. Fully implemented, these complex biosensor systems will
generate prodigious volumes of longitudinal clinical data that qualify as Personal Health
Information. Structures will be required to securely warehouse, and policies established
to define legal entities that control and have access to, this confi dential HIPAA (Health
Insurance Portability and Accountability Act)-protected health information. Biosensor
systems will produce clinically actionable data driving patient management, and the
science of healthcare delivery will need to create new methods to eff ectively
and economically operationalize and deploy this information. Moreover, Payors will have
to develop policies and procedures that quantify the value proposition of this new
technology to determine whether this approach to disease prevention and wellness
maintenance economically unburdens the healthcare system, to defi ne reimbursement
strategies.
Technology that anticipates heart attacks before they happen, predicts the occurrence of
strokes, and identifi es the earliest stages of cancer before it comes to clinical attention
would truly transform global health. Emerging tools in the clinical armamentarium to
accelerate that transformation include implantable biosensors that bridge the temporal
gap in disease management. This revolution in disruptive innovation will evolve at the
interface of biology, engineering, and clinical medicine. It will require parallel
innovations in regulatory science, health policy, and the science and economics of
healthcare delivery. Moreover, it will require the combined efforts of diverse
communities of practice, which have traditionally remained independent silos. Although

the challenges are great, implantable devices have the potential to fully realize the benefi
ts of individualized medicine, and drive the evolution of healthcare from palliation to
prevention, shifting the focus from disease mitigation to maintenance of longitudinal
wellness.
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